Accordingly, CDH22 deregulation was associated with clinical outcome in other cancer types: loss of CDH22 protein expression was correlated with melanoma progression, and with worse 5-year PFS, and a similar, though not significant pattern, was observed for 5-year OS [16]; in colorectal cancer CDH22 overexpression was significantly and positively correlated with progression, invasion, metastasis and clinical stage of patients [17]. The gene discussed is CDH22; the disease is melanoma.